Keyword: Zynteglo

Bluebird Bio CEO snares $24 million pay package as gene therapy advance

4. Zynteglo

Bluebird Bio’s LentiGlobin is trying to deal with the underlying genetic cause of the inherited blood disorder beta thalassemia. But as with any gene therapy that aims to cure a complex disease with a single infusion, pricing and access are major challenges.